Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933547 | 0.86 | NPC1 (0.39) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL30933550 | 0.82 | GAA (0.42) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL657838 | 0.78 | MAPT (0.40) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL5166376 | 0.77 | SYK (0.45) | MAPTNPC1RAB9AALDH1A1SYK | |
| SCHEMBL12319727 | 0.77 | PARP1 (0.40) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31017007 | 0.77 | ALDH1A1 (0.41) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL17083242 | 0.75 | NPC1 (0.39) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL30933549 | 0.74 | CTSD (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1HTR2C | |
| SCHEMBL30933579 | 0.73 | MAPT (0.33) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL224636 | 0.71 | TRPA1 (0.42) | MAPTNPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010077589-A2 | STAT3 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN OFFICE OF TECHNOLOGY TRANSFER (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010025235-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | MAPT 4008/4885NPC1 1999/4885RAB9A 2010/4885 |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | STAT3, JAK2, STAT6 | MAPT 4415/4885NPC1 3369/4885RAB9A 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.